Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5
16 August 2022 - 11:00PM
Artelo Biosciences,
Inc.
(Nasdaq: ARTL), a
clinical-stage pharmaceutical company focused on modulating
lipid-signaling pathways to develop treatments for people living
with cancer, pain, and neurological conditions, today announced
publication of pre-clinical results indicating a novel fatty acid
binding protein 5 (FABP5) inhibitor from the Company’s FABP
inhibitor platform reduces anxiety behaviors in an area of the
brain known to be important in anxiety and that modulation of the
FABP5 system may serve as a promising target for the development of
novel anxiolytics.
“What was particularly interesting was that we have demonstrated
that the CB2 receptor, which is often thought of as the peripheral
cannabinoid receptor, is involved in the control of both fear and
anxiety and, importantly, is capable of being modulated by FABP5
inhibition for the first time,” said Gregory D. Gorgas. President
and Chief Executive Officer of Artelo Biosciences. “This new data
further supports the development of our FABP inhibitor platform in
anxiety-related disorders such as post-traumatic stress
disorder.”
“Despite the involvement of endogenous cannabinoid signaling in
many psychiatric conditions, including anxiety disorders, the
effects of FABPs on the modulation of fear and anxiety have not
been thoroughly investigated,” said neuroscience Professor Steven
R. Laviolette, Ph.D., one of the lead researchers of the study. “We
are encouraged by these findings which indicate inhibiting FABPs
represents a promising neurobiological approach for the development
of novel anxiety-inhibiting pharmacotherapies.”
This research, with one of many of Artelo’s FABP inhibitors,
which was led by Taygun C. Uzuneser, Ph.D., and Steven R.
Laviolette, Ph.D., both of the University of Western Ontario,
London, Ontario, was published in the journal Cerebral Cortex.
Another researcher involved in the study was Iwao Ojima, Ph.D.,
University Distinguished Professor at Stony Brook University and
the principal inventor of the multiple FABP inhibitors exclusively
licensed to Artelo, including the Company’s lead FABP inhibitor
ART26.12 being developed as a potential treatment for Chemotherapy
Induced Peripheral Neuropathy.
About Artelo’s Platform of FABP InhibitorsFABPs
are a family of intracellular proteins that chaperones lipids
including endocannabinoids and fatty acids. Inhibitors of FABPs are
intended for treatment of cancer, neuropathic and nociceptive pain,
and anxiety. Artelo licensed multiple compounds through its
collaboration with Stony Brook University. The Company’s lead
compound, ART26.12, is a selective inhibitor of FABP5. Artelo’s
near-term goal is to develop ART26.12 for the prevention and/or
treatment of Chemotherapy Induced Peripheral Neuropathies, for
which there are no regulatory approved medicines. While progressing
the lead FABP inhibitor in regulatory-enabling studies, additional
compound(s) have been identified and selected for advancement in
anxiety-related disorders, including Post-Traumatic Stress
Disorder.
About Artelo BiosciencesArtelo
Biosciences, Inc. is a clinical-stage pharmaceutical company
focused on modulating lipid-signaling pathways to develop
treatments for people living with cancer, pain, and neurological
conditions. Artelo is advancing a portfolio of broadly applicable
product candidates designed to address significant unmet needs in
multiple diseases and conditions, including anorexia, cancer, PTSD,
pain, and inflammation. Led by proven pharmaceutical executives
collaborating with highly respected researchers and technology
experts, Artelo applies leading edge scientific, regulatory, and
commercial discipline to develop high-impact therapies. More
information is available at www.artelobio.com and
Twitter: @ArteloBio.
Forward Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to Artelo’s product development,
clinical and regulatory timelines, market opportunity, competitive
position, possible or assumed future results of operations,
business strategies, potential growth opportunities and other
statement that are predictive in nature. These forward-looking
statements are based on current expectations, estimates, forecasts
and projections about the industry and markets in which we operate
and management’s current beliefs and assumptions. These statements
may be identified by the use of forward-looking expressions,
including, but not limited to, “expect,” “anticipate,” “intend,”
“plan,” “believe,” “estimate,” “potential,” “predict,” “project,”
“should,” “would” and similar expressions and the negatives of
those terms. These statements relate to future events or our
financial performance and involve known and unknown risks,
uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Such factors include those set
forth in Artelo’s filings with the Securities and Exchange
Commission, including our ability to raise additional capital in
the future. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of
the date of this press release. Artelo undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise, except to the
extent required by applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Apr 2023 to Apr 2024